In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
about
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signalingEverolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer.The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.mTOR function and therapeutic targeting in breast cancer.A genome-wide association study reveals candidate genes for the supernumerary nipple phenotype in sheep (Ovis aries).Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report.Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.Emerging data on improving response to hormone therapy: the role of novel targeted agents.Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.Treatment of melanoma with selected inhibitors of signaling kinases effectively reduces proliferation and induces expression of cell cycle inhibitors.Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.Transcriptomic response of breast cancer cells to anacardic acid.
P2860
Q33903949-72ACD83C-5E8E-4A81-A26F-B44A60DE0A91Q35807838-2A59A7B6-0C35-43FE-AEDA-5CBBEF271AF0Q36078905-69886E91-E59A-43C6-8D95-D20318CB9D72Q36879496-9E1D78D6-99B3-4E12-9C9D-C2050C9A1E1AQ37190310-99C73843-974C-4483-81BB-35AF5AB87877Q37702577-0263BFB3-F198-4A57-A609-27648E7426A2Q37743486-A135C19A-4F16-409D-98F2-F67CE455697AQ38431300-D8933C53-DD26-467B-A239-EC52B22CAF56Q40510800-745C1E1C-A299-48B3-998C-2B4A6A6B5D45Q41142443-105C028A-4CF9-4273-86D6-5598402D726DQ41619667-C4F819EB-864B-4BD5-9788-EE5850B23FB7Q46537162-EE0C559C-E496-4D9E-B90E-FEC6E70791C8Q47101508-4ECC1A24-128B-4F37-8711-267EF08DB237Q47321072-A7DC46B8-F232-48BA-A6FF-E52561067F00Q54112994-88893C4E-0231-44D5-8829-075F52BEC648Q55061507-97C8E049-D787-4B9A-8163-BD1BDED854D9
P2860
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
In vitro activity of the mTOR ...... is for predictors of response.
@en
type
label
In vitro activity of the mTOR ...... is for predictors of response.
@en
prefLabel
In vitro activity of the mTOR ...... is for predictors of response.
@en
P2093
P2860
P1476
In vitro activity of the mTOR ...... is for predictors of response.
@en
P2093
Amrita J Desai
David Chen
Dennis J Slamon
Dylan Conklin
Lee Anderson
Neil A O'Brien
Ondrej Kalous
Richard S Finn
Ronald Linnartz
Sara A Hurvitz
P2860
P2888
P304
P356
10.1007/S10549-015-3282-X
P407
P50
P577
2015-02-08T00:00:00Z
P5875
P6179
1036693108